Forensic Analysis · Consulting & Engineering Services · as of Nov 10, 2026

Charles River Laboratories International, Inc. (CRL)

A forensic read on Charles River Laboratories International, Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.

C · Mixed — selective

Forensic grade

Grey Zone

Financial health

1.8

Distress distance

Clean

Earnings quality

Forensic signals

-4.4%

ROE

-0.9%

Revenue growth

This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (auditor quality, say on pay, board independence, going concern). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.

Charles River Laboratories International, Inc. earns a C (Mixed — selective) forensic quality grade, and its balance-sheet distress test reads 1.8, placing it in the Grey zone. 2 forensic signals were flagged in its latest SEC filings, led by return on invested capital.

What the filings flag

0.3%

FY2025

Return on invested capital. Return on invested capital is 0.3% in the latest fiscal year and slipping across FY2023–FY2025 from 7.4%. After-tax operating profit was $510M in FY2023 and $20M in FY2025, with operating income at 14.9% of revenue in FY2023, 5.6% in FY2024 and 0.6% in FY2025. The capital base behind it came down -12% across FY2023–FY2025, from $6.9B to $6.1B, so this return is struck on a smaller base than it started on. FY2025's operating profit carried a $165M goodwill write-off and a $100M restructuring charge that alone took about 3.4 points off that year's return, so about 3.4 of the 7.1-point fall across FY2023–FY2025 is that charge landing in the latest year rather than the capital earning less. FY2024's operating profit carried a $215M goodwill write-off and a $107M restructuring charge that alone took about 3.2 points off that year's return; FY2024 sits between the two ends of FY2023–FY2025, so the charge shapes the path between them without moving the change across it. A non-cash write-down lowers the reported return in the year it lands.

$380M

FY2024–FY2025

Goodwill impairments. Took $380M of goodwill writedowns across 2 years (FY2024 ($215M), FY2025 ($165M)). Writedowns mean past acquisitions underperformed what was paid for them.

Key fundamentals

Latest Revenue$4.02B

Revenue Growth YoY-0.9%

Revenue CAGR (2yr)-1.4%

Net Margin-3.6%

Free Cash Flow$518.5M

Return on Equity-4.4%

Debt / Equity0.68x

The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Charles River Laboratories International, Inc.'s actual 10-K/10-Q/8-K filings?

Generate the AI investment read →

No credit card · informational only, not investment advice · see the track record

← Browse all forensic stock analyses

Data from SEC EDGAR public filings · metrics as of Nov 10, 2026. Forensic signals flag probability, not certainty.

See a wrong number? Report an error with the filing it should match.